Profile of temsirolimus in the treatment of advanced renal cell carcinoma

被引：8
作者：
Staehler, Michael [1 ]
Haseke, Nicolas [1 ]
Khoder, Wael [1 ]
Stief, Christian G. [1 ]
机构：
[1] Univ Munich, Dept Urol, Klinikum Grosshadern, D-81377 Munich, Germany
来源：
ONCOTARGETS AND THERAPY | 2010年 / 3卷
关键词：
renal cell cancer; nonclear cell renal cancer; temsirolimus; first-line therapy; overall survival; nephrectomy; INTERFERON-ALPHA; PROGNOSTIC-FACTORS; SURVIVAL; NEPHRECTOMY; CANCER;
D O I：
10.2147/OTT.S7657
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.
引用
收藏
页码：191 / 196
页数：6
相关论文
共 16 条
  • [1] [Anonymous], 2008, SEER CANC STAT REV 1
  • [2] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Atkins, MB
    Hidalgo, M
    Stadler, WM
    Logan, TF
    Dutcher, JP
    Hudes, GR
    Park, Y
    Lion, SH
    Marshall, B
    Boni, JP
    Dukart, G
    Sherman, ML
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 909 - 918
  • [3] Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
    Dutcher, Janice P.
    de Souza, Paul
    McDermott, David
    Figlin, Robert A.
    Berkenblit, Anna
    Thiele, Alexandra
    Krygowski, Mizue
    Strahs, Andrew
    Feingold, Jay
    Hudes, Gary
    [J]. MEDICAL ONCOLOGY, 2009, 26 (02) : 202 - 209
  • [4] DUTCHER JP, 2008, CLIN ONCOL S, V26
  • [5] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Escudier, Bernard
    Pluzanska, Anna
    Koralewski, Piotr
    Ravaud, Alain
    Bracarda, Sergio
    Szczylik, Cezary
    Chevreau, Christine
    Filipek, Marek
    Melichar, Bohuslav
    Bajetta, Emilio
    Gorbunova, Vera
    Bay, Jacques-Olivier
    Bodrogi, Istvan
    Jagiello-Gruszfeld, Agnieszka
    Moore, Nicola
    [J]. LANCET, 2007, 370 (9605) : 2103 - 2111
  • [6] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 125 - 134
  • [7] Sequential Therapy in Renal Cell Carcinoma
    Escudier, Bernard
    Goupil, Marine Gross
    Massard, Christophe
    Fizazi, Karim
    [J]. CANCER, 2009, 115 (10) : 2321 - 2326
  • [8] FIGLIN RA, 2009, CANCER, P3651
  • [9] Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
    Flanigan, RC
    Mickisch, G
    Sylvester, R
    Tangen, C
    Van Poppel, H
    Crawford, ED
    [J]. JOURNAL OF UROLOGY, 2004, 171 (03) : 1071 - 1076
  • [10] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Hudes, Gary
    Carducci, Michael
    Tomczak, Piotr
    Dutcher, Janice
    Figlin, Robert
    Kapoor, Anil
    Staroslawska, Elzbieta
    Sosman, Jeffrey
    McDermott, David
    Bodrogi, Istvan
    Kovacevic, Zoran
    Lesovoy, Vladimir
    Schmidt-Wolf, Ingo G. H.
    Barbarash, Olga
    Gokmen, Erhan
    O'Toole, Timothy
    Lustgarten, Stephanie
    Moore, Laurence
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) : 2271 - 2281
12